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Abstract
Background: Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to characterize the
genetic evolution to daptomycin resistance in S. aureus.
Methods: Whole genome sequencing was performed on a unique collection of isogenic, clinical (21 strains) and laboratory
(12 strains) derived strains that had been exposed to daptomycin and developed daptomycin-nonsusceptibility. Electron
microscopy (EM) and lipid membrane studies were performed on selected isolates.
Results: On average, six coding region mutations were observed across the genome in the clinical daptomycin exposed
strains, whereas only two mutations on average were seen in the laboratory exposed pairs. All daptomycin-nonsusceptible
strains had a mutation in a phospholipid biosynthesis gene. This included mutations in the previously described mprF gene,
but also in other phospholipid biosynthesis genes, including cardiolipin synthase (cls2) and CDP-diacylglycerol-glycerol-3-
phosphate 3-phosphatidyltransferase (pgsA). EM and lipid membrane composition analyses on two clinical pairs showed
that the daptomycin-nonsusceptible strains had a thicker cell wall and an increase in membrane lysyl-phosphatidylglycerol.
Conclusion: Point mutations in genes coding for membrane phospholipids are associated with the development of reduced
susceptibility to daptomycin in S. aureus. Mutations in cls2 and pgsA appear to be new genetic mechanisms affecting
daptomycin susceptibility in S. aureus.
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Introduction
Staphylococcus aureus is one of the most significant human bacterial
pathogens,causingimmense morbidityandmortalityinhospitalised
patients, as well as in the community. It causes a diverse range of
clinical disease, with mortality from infection reported as high as
35% [1]. Compounding this severity of disease is the constant
adaptationof the bacteria to antibiotic pressure, with the emergence
of resistance in S. aureus now being one of the most important public
health problems in the developed world. As a consequence of this
resistance, reliance on ‘last-line’ anti-staphylococcal agents such as
vancomycin, linezolid, and daptomycin has increased dramatically
over recent years, and unfortunately, reduced susceptibility to these
agents has also been described [2,3].
Daptomycin is a cyclic lipopeptide antibiotic that has recently
been FDA approved for the treatment of complicated skin and soft
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sided endocarditis [2]. Understanding the mechanism of action of
daptomycin has remained challenging, but current evidence
indicates that it interacts with the bacterial cytoplasmic membrane
in a calcium-dependent manner, leading to potassium efflux and
membrane depolarisation, with subsequent cell death [4,5]. Using
model membranes, it has been shown that negatively charged
lipids in the presence of calcium allow daptomycin to insert and
perturb bilayer membranes [4]. Importantly, the majority of S.
aureus membrane lipids are comprised of negatively charged
phospholipids: phosphatidylglycerol (PG) and cardiolipin [4].
Therapeutic failures with daptomycin for infections due to S. aureus
have now been reported, with many ofthese being associated withthe
evolution of reduced susceptibility to daptomycin in the setting of
deep-seated and poorly controlled infection [2,6,7,8]. The mecha-
nisms of daptomycin resistance in S. aureus havefocused on the roleof
the staphylococcal membrane protein, MprF. MprF is a bifunctional
protein that mediates both the lysinylation of PG and its translocation
to the outer leaflet of the membrane [9]. Point mutations within
MprF have been described in S. aureus strains with reduced
susceptibility to daptomycin, and such mutations appear to cause a
gain-in-function, hypothesized to result in accelerated membrane
translocation of Lysyl-PG (L-PG), thereby resulting in a reduced net-
negative membrane charge that may electrostatically repel calcium-
complexed daptomycin [10]. Other mutations that have been
reported include mutations in walK (previously yycG), which encodes
a sensor histidine kinase that regulates cell wall metabolism and
virulence, and a point mutation in each of rpoB and rpoC,e n c o d i n g
subunits of RNA polymerase [11]. Furthermore, increased expression
of the dltABCD operon, which is responsible for D-alanylating wall
teichoic acids and contributes to the net-positive surface charge, has
been shown to be associated with reduced susceptibility to
daptomycin [10]. Thus far, the study of the genetic mechanisms of
daptomycin resistance have been limited to analyses of single pairs of
isolates or isolates that are laboratory derived [11,12,13,14].
To elucidate the genetic factors involved in the evolution of
reduced susceptibility to daptomycin in S. aureus, we performed
whole genome sequencing of 33 carefully selected strains, which
included nine clinical isogenic pairs or series (21 strains) and nine
laboratory derived mutants from three parent strains (12 strains).
We identified previously described mutations associated with
daptomycin resistance such as mprF, walK and rpoB but most
importantly, we identified novel mutations in two genes respon-
sible for the production of the anionic membrane phospholipids,
PG and cardiolipin. In select clinical pairs, these mutations were
associated with changes in phospholipid membrane composition
that would explain a reduced affinity for daptomycin, and changes
in cell wall thickness. This study represents the first large-scale
comparative assessment of genome-wide factors involved in
daptomycin-nonsusceptibility in staphylococci derived from active
clinical infections.
Methods
Ethics Statement
The clinical S. aureus isolates used in this study were referred to
our laboratory due to persistence during daptomycin therapy.
Ethics approval was not required for this laboratory study, as no
patient identifiers or clinical details apart from the site where the
culture was taken (eg blood, bone or heart valve) was obtained. As
referenced in Table 1, some of the strains were from previously
published work and some of these publications contain clinical
information.
Bacterial strains and culture conditions
Isolates obtained from the same patient were previously
confirmed to be isogenic based on pulsed-field gel electrophoresis.
All bacteria were stored at 280uC until further testing. Daptomycin
(Cubist, MA) susceptibility testing was performed by broth
macrodilution using cation-adjusted Mueller-Hinton II broth (BD)
supplementedto containa final calcium concentration of 50 mg/ml.
To determine the differences between in vivo and in vitro daptomycin
exposure on the genetic evolution to resistance, three reference S.
aureus strains underwent in vitro daptomycin exposure. A prototype
hospital-acquired MRSA strainwas selected (MRSA32 [A5948]), as
well as an agr+ (RN6607 [A8115]) and its isogenic agr2 mutant
strain (RN9120 [A8117]). The latter two strains also enabled an
assessment of the effect of agr on daptomycin resistance. In vitro
daptomycin exposure was performed in Brain Heart Infusion (BHI)
broth using a high bacterial inoculum (10
8 CFU/ml) and 48 hour
exposuretodaptomycinata concentrationof8 mg/ml at35uC.The
culture wasthen platedonto agar containingvarying concentrations
of daptomycin, and single colonies were chosen for formal
susceptibility testing. Three independent mutants from each
reference strain were selected for sequencing. One of the mutants
from A5948 was generated previously (A6658) [15].
Whole genome sequencing
Genomic DNA was extracted according to manufacturer’s
guidelines (Promega Wizard Genomic Kit). All daptomycin-
susceptible parent genomes were sequenced using 454 FLX
pyrosequencing (Roche) with DNA fragment libraries according
to the manufacturer’s recommendations. Genomes were assembled
using Newbler and the runAssembly script was then used to
assemble reads into contigs. To remove contaminating sequences,
final assemblies were BLASTed to the NCBI non-redundant (NR)
database and UniVecCore. Assembly annotation was performed
using a combination of ab initio and evidence-based approaches. For
further details see supplementary material (Text S1). A summary of
gene finding data foreachlocus canbe viewed at theBroad Institute
S. aureus Drug Resistance Project group database (http://www.
broadinstitute.org/annotation/genome/staphylococcus_aureus_
drug_resistance/).
Single Nucleotide Polymorphism (SNP) and Phylogenetic
Analysis
The daptomycin-nonsusceptible daughter strains were sequenced
to high coverage ($100 fold) with 76 nucleotide reads produced on
the Illumina platform. The reads were used to call SNPs against the
parent assemblies using the variant ascertainment algorithm (VAAL),
a polymorphism discovery algorithm for short reads developed by the
Broad Institute [16]. Select SNPs were confirmed independently
using PCR sequencing. Phylogenetic analysis was performed using
single-copy core gene trees that were generated from orthologous
groups computed by orthoMCL (http://www.orthomcl.org/cgi-bin/
OrthoMclWeb.cgi) [17]. An all versus all BLAST was performed
using the predicted protein sequence from all genomes of interest. All
BLAST hits with an e-value,1e
25 were used as input to orthoMCL.
To generate trees, nucleotide sequences for all single-copy core genes
were retrieved and aligned by orthologous group [18]. These
alignments were trimmed using trimAL to allow concatenation [19].
Aligned, trimmed and concatenated sequences were then used to
build trees using FastTree [20]. Using the genome sequence for all
parent strains, multi-locus sequence types (MLST) were also
determined (http://saureus.mlst.net/). This is a well established
method for determining clonality in S. aureus and utilizes the sequence
of seven house-keeping genes to determine allelic profiles [21].
S. aureus Genomics and Daptomycin
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determined using TMHMM v 2.0 [22].
Membrane lipid analysis
Lipid measurements were performed after a modified Bligh and
Dyer extraction of the total polar lipids [23] and quantified using
LC-MRM (multiple reaction monitoring) as described in supple-
mentary material (Text S1). Three independent colonies from
each strain were assessed and each extract was run in triplicate.
Differences in the PG:L-PG ratio were assessed by student’s t test
at a significance level of P#0.05.
TEM
Cells were prepared for TEM as described previously [5]. In
brief, cells from late-exponential phase were fixed with 2.5% (vol/
vol) glutaraldehyde and 2.0% (wt/vol) osmium tetroxide, and then
stained with 2.0% (wt/vol) uranyl acetate. After embedding in LR
White resin and cutting thin sections, samples were further stained
with uranyl acetate and then imaged using a LEO 912AB
microscope. The cell wall of 100 cells for each strain were
measured in a blinded fashion and compared using the student’s t
test with a significance level of P#0.05.
Results and Discussion
Clinical and laboratory S. aureus strains exposed to
daptomycin
The characteristics of the S. aureus strains used in this study are
shown in Tables 1 and 2. All the clinical pairs or series of S. aureus
were obtained from patients with bloodstream infection who failed
or had persistent infection while being treated with daptomycin.
Most were complicated by endocarditis or other deep-seated
infection (Table 1). Each pair or series includes the initial infecting
isolate, which was daptomycin-susceptible (MIC#1 mg/ml), and
the subsequent isolate/s that were daptomycin-nonsusceptible
after daptomycin exposure. For most strains, exposure to
daptomycin did not change the MIC to vancomycin (Table 1
and 2). The increase in MIC to daptomycin for the laboratory
exposed strains was equivalent to that seen for the clinical isolates,
with no differences observed between agr+ S. aureus (A8115) and its
isogenic agr2 (A8117) mutant strain (Table 2). In vitro selection has
the advantage of assessing genetic changes specific to daptomycin
exposure alone, but is limited by the absence of host factors and
immune responses that may alter the evolution of daptomycin
resistance. This unique collection of carefully selected isogenic S.
aureus strains provided us with an excellent opportunity to
investigate the mechanisms of resistance to one of our last line
anti-staphylococcal antibiotics, daptomycin.
Whole genome sequencing of daptomycin-susceptible S.
aureus parent strains
All daptomycin-susceptible parent genomes were sequenced
to an average of 24-fold coverage (range 14- to 39-fold) and
were of similar sizes, ranging from 2.72 Mb to 2.97 Mb (mean
of 2.84 Mb). The mean number of putative open reading frames
was 2757 (range 2539–3066) and the percentage GC content
was similar between strains (mean 32.72%, range 32.58%–
32.84%) (http://www.broadinstitute.org/annotation/genome/
Table 1. Characteristics of the daptomycin-exposed clinical strains of Staphylococcus aureus used in this study.
Dp-exposed pairs/series Clinical syndrome Antibiotic susceptibility MLST Type Source
Dp MIC (ug/ml) Vn MIC (ug/ml)
1) A8819 Bacteremia, 0.25 1 105 Boston
A8817 OM, Septic arthritis 2 1
2) A10102 Bacteremia 0.5 1 5 [2]
A10103 2 1
3) A9299 Bacteremia 0.25 1–2 5 New York
A9305 Endocarditis 2 1
4) A9719 Bacteremia, 0.25 1–2 5 Western
A9744 Endocarditis 2 2 Massachusetts
5) A9754 Bacteremia 0.5 2 8 Boston
A9757 Endocarditis 4 2
6) A8796 Bacteremia 0.5 1 105 Boston [7]
A8799 Vertebral OM 2 2
7) A9763 Bacteremia 0.5 1 5 Chicago [6]
A9764 OM, PJI 4 2
8) A9765 Bacteremia 0.5 1 8 Chicago [6]
A9766 OM 2 2
9) A9781 Bacteremia 0.5 1 5 Boston
A9784 0.5
A9788 1
A9792 2
A9798 2 2
Dp, daptomycin; MLST, multi-locus sequence type; OM, osteomyelitis; PJI, prosthetic joint infection; Vn, vancomycin.
doi:10.1371/journal.pone.0028316.t001
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and 2, seven of the parent strains were sequence type (ST) 5 and
t h r e ew e r eS T 8 ,w h i c ha r et h em o r ec o m m o nM L S Tt y p e si n
hospital-acquired S. aureus in North America [24]. Two parent
s t r a i n sw e r eS T 1 0 5 ,w h i c hh a sb e e nl e s sc o m m o n l yr e p o r t e d
(http://saureus.mlst.net/). Detailed phylogenetic analysis is
shown in Fig. S1, and illustrates the high degree of genetic
conservation between the parent strains isolated from different
patients in this study.
Number and type of genetic mutations associated with
daptomycin exposure
To investigate the genetic mutations associated with the in vivo
or in vitro evolution of daptomycin resistance, all isogenic daughter
strains (21 strains) were sequenced and compared to their
daptomycin-susceptible parent strains. On average, only six coding
region mutations were observed across the entire genome in the
clinical in vivo daptomycin exposed strains (range 2–13 mutations),
whereas only two mutations on average (range 1–4 mutations)
were seen in the laboratory in vitro exposed pairs (Table S1). In the
clinical pairs, the majority of mutations were SNPs (mean 4, range
2–8), with an average of 2 insertions or deletions per pair. All but
three SNPs led to an amino acid change in their respective
proteins (Table S1). Mutated genes were categorized by function
to identify themes of bacterial physiology that may contribute
towards reduced susceptibility to daptomycin (Fig. 1). Interesting-
ly, the most consistent mutation, which was found in all 12 strain
pairs, was a mutation in a gene important for membrane
phospholipid biosynthesis, highlighting the central aspect of cell
membrane physiology to susceptibility to daptomycin.
Mutations within genes associated with phospholipid
biosynthesis
Daptomycin is an anionic molecule but when complexed with
calcium ions, its properties and mode of action are analogous to
cationic antimicrobial peptides [9,25], where interaction with the
negatively-charged cell membrane leads to membrane perturba-
tion and cell lysis [4,5]. The gene most frequently mutated in our
daptomycin-resistant strains was mprF. Point mutations in this gene
were found in all nine clinical pairs and one laboratory-derived
pair (Table 3 and S1). This gene codes for a large membrane
protein that contains 14 transmembrane domains (TMDs), and
serves two key functions; the addition of positively charged lysine
residues onto PG to form L-PG, which is mediated by a C-terminal
lysinylation domain, and the translocation of this L-PG to the
outer leaflet of the cytoplasmic membrane, which is mediated by
the N-terminal translocation domain [9]. This acts to neutralize
membrane charge and creates resistance to cationic peptides such
as host immune factors and daptomycin, and highlights its
importance in bacterial immune evasion and fitness within the
host [9,26]. It has been previously shown that mprF point
mutations in daptomycin-nonsusceptible isolates are associated
with a gain-in-function, leading to greater L-PG in the outer leaflet
of the membrane and a further reduction in the net-negative
membrane charge leading to electrorepulsion [26].
The predicted amino acid changes associated with the 11 SNPs
identified within mprF in this study are shown in Fig. 2A. All SNPs
were independently confirmed by PCR and sequencing. Eight
SNPs were mapped to four positions within the lysinylation and
translocation domains (Fig. 2A). One SNP (G61V) was found
within the N-terminal translocation domain only, and two SNPs
were mapped to one position (L826F) in the C-terminal
lysinylation domain only (Fig. 2A). We hypothesize that the latter
two predicted amino acid changes may either directly enhance
translocation of L-PG to the bacterial surface by increasing
translocase activity of MprF, or enhance lysinylation of PGs
leading to increasing pools of L-PG on the inner leaflet of the
membrane [9]. Accumulation of intracellular L-PG may stimulate
translocation to the outer leaflet of the membrane in a gradient-
dependent manner. This would, in turn, exacerbate the reduced
net-negative charge of the bacterial surface, thus contributing to
daptomycin non-susceptibility [9,10,26]. The importance of
mutations within MprF to daptomycin susceptibility is also shown
Table 2. Characteristics of the daptomycin-exposed laboratory strains of Staphylococcus aureus used in this study.
Laboratory Dp-exposed pairs
a Antibiotic susceptibility MLST Type Source
Dp MIC (ug/ml) Vn MIC (ug/ml)
1) A8115
b 0.5 1 5 R. Novick
A10135 2 1
A10151 4 1
A10152 2 1
2) A8117
c 0.5 1 5 R. Novick
A10136 2 1
A10153 2 2
A10154 2 2
3) A5948
d 1 1 8 [15]
A6658 2 1
A10155 2 1
A10156 2 0.5
Dp, daptomycin; MLST, multi-locus sequence type; Vn, vancomycin.
aThree individual mutants were generated from each daptomycin-susceptible laboratory parent strain. The three mutants are represented for each susceptible strain.
bRN6607 (agr+).
cRN9120 (agr2).
dMRSA32.
doi:10.1371/journal.pone.0028316.t002
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As shown in Table 1 and S1, the MIC to daptomycin increased to
the nonsusceptible range once the mprF mutation occurred in
A9792 (S295L). Interestingly, the final isolate of the series (A9798)
had a different mprF mutation (G61V) compared to its predecessor
(A9792), and both strains had mutations in genes not found in the
other. This suggests that multiple resistant subpopulations are
likely to have been present rather than a step-wise accumulation in
mutations. Finally, not all daptomycin-nonsusceptible mutants had
mprF mutations, particularly the laboratory-derived strains,
suggesting that host pressures, such as cationic antimicrobial
peptides, may influence MprF-mediated daptomycin resistance.
Mutations in a second phospholipid biosynthesis gene were
identified in five of the studied pairs (Tables 3 and S1). This gene
was cardiolipin synthase (cls2), mutations of which may have been
predicted to have a role given observations of altered gene
expression in a laboratory-derived daptomycin-nonsusceptible
strain [27]. Cardiolipin is an important anionic membrane
phospholipid that is synthesized from the phosphatidyl moiety of
two PG molecules by the membrane-bound enzyme, Cls [28].
Under conditions of stress, such as unfavorable growth conditions
or cell-wall acting antibiotics, cardiolipin can accumulate up to
,25%–30% of membrane phospholipid [28]. Cardiolipin syn-
thase is predicted to contain two TMDs, spanning residues 13–35
and 45–67, as well as two putative cardiolipin synthase domains
across residues 229–256 and 407–434 (Fig. 2B). The four SNPs
identified within Cls2 reside exclusively within the two putative
TMDs at the N-terminus of the protein (Fig. 2B). All mutations
were independently confirmed by PCR and sequencing. Impor-
tantly, two of the laboratory-derived daptomycin-nonsusceptible
mutants (A10151 and A10155) from two distinct parent strains
(A8115 and A5948; Tables 3 and S1), had only a single point
mutation in cls2, both at the same position and involving the same
amino acid change (Thr33Asn). This single point mutation in cls2
caused an increase in MIC to daptomycin from 0.5 mg/ml to
$2.0 mg/ml in both pairs. No other gene mutations were
identified in these two pairs based on the whole genome sequence.
We hypothesise that mutations within the TMDs impair
membrane localisation and function of Cls, resulting in altered
cardiolipin synthesis. These changes alone, or in concert with an
mprF mutation, which was seen in three of the clinical pairs
(Table 3), may be important in the charge-based repulsion of
daptomycin, or may alter binding of daptomycin to the
membrane. Interestingly, it has previously been shown that cls
gene expression, as determined by microarray analysis, was
repressed in a laboratory-derived daptomycin-nonsusceptible
mutant but mutations in the gene were not assessed [27]. Finally,
adding strength to the role of cls in daptomycin susceptibility, two
Figure 1. Percentage of daptomycin-exposed pairs (n=12) with a mutation in each functional gene category. All daptomycin-
nonsusceptible isolates had at least one mutation in a gene coding for phospholipid biosynthesis, including mprF, cls2 or pgsA.
doi:10.1371/journal.pone.0028316.g001
Table 3. Predicted protein changes in clinical- and
laboratory-derived daptomycin-nonsusceptible isolates of
Staphylococcus aureus.
Dp-nonsusceptible
strains
a Predicted Amino acid Change
MprF Cls2 PgsA
Clinically-derived
1) A8817 T345I F60S
2) A10103 S295L
3) A9305 S295L
4) A9744 S337L A23V
5) A9757 I420N
6) A8799 S337L
7) A9764 L826F L52F
8) A9766 S295L
9) A9792 S295L
A9798 G61V
Laboratory-derived
b
1) A10135 A64V
A10151 T33N
A10152 A64V
2) A10136 S177F
A10153 A64V
A10154 K65R, insert G76, E77
3) A6658 L826F
A10155 T33N
A10156 V59N
Dp, daptomycin.
aEach daptomycin-nonsusceptible strain was derived from a daptomycin-
susceptible parent strain shown in table 1. The predicted amino acid change
relates to the gene mutation between the listed strain and its susceptible
parent.
bThree individual mutants were generated from each daptomycin-susceptible
laboratory parent strain. The three mutants are represented for each
susceptible strain.
doi:10.1371/journal.pone.0028316.t003
S. aureus Genomics and Daptomycin
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susceptibility to daptomycin in clinical strains of Enterococcus
[29,30].
A third gene novel to daptomycin susceptibility and also
involved in membrane phospholipid biosynthesis was also
identified, known as CDP-diacylglycerol-glycerol-3-phosphate 3-
phosphatidyltransferase (pgsA). PgsA is important in the production
of PG, the most abundant anionic membrane phospholipid.
Interestingly, mutations in pgsA have recently been described to be
associated with reduced susceptibility to daptomycin in Bacillus
subtilis [31]. Our mutations were only identified in laboratory-
exposed strains; however as shown for cls, a point mutation in pgsA
alone (strain A10152) was enough to cause an increase in MIC of
daptomycin from 0.5 mg/ml to 2 mg/ml (Tables 2 and S1). Five
SNPs were mapped to three positions of the protein, and as seen
with cls mutations, all these SNPs were within TMDs (Fig. 2C).
One in-frame insertion was also identified (Table 3 and Fig. 2C).
Our hypothesis is that these mutations impair PgsA function
leading to reduced PG in the membrane and subsequent surface
charge alterations. Further work is required to characterize the
role of this gene in S. aureus susceptibility to daptomycin. The
interaction and significance of mutations in these three phospho-
lipid biosynthesis genes to daptomycin susceptibility is shown in
figure 3.
Host pressure and daptomycin exposure lead to
mutations across a functionally diverse array of genes
We observed a greater number of mutations in our clinical
versus laboratory-derived pairs, highlighting the importance of
host immune pressures on the genetic response of S. aureus to an
antimicrobial. Apart from mutations in phospholipid biosynthesis
genes, five of the clinical pairs had at least one mutation in a gene
encoding a transcriptional regulator or a two-component signal
transduction system (Fig. 1 and Table S1). These included walK
(previously yycG), agr, stp1, tcaR and rsbU (sigma-B regulation),
which are all important cell wall biosynthesis and/or virulence
regulators, with the majority being reported for the first time
relating to daptomycin exposure. Despite mutations in rpoB being
initially reported with a laboratory-derived daptomycin-nonsus-
ceptible isolate [11], we identified only two pairs (clinical) that had
mutations within rpoB (Table S1). Less common mutations were
observed in other systems of physiological function including
carbohydrate and amino acid metabolism, ion and small molecule
transporters, and housekeeping genes (Fig. 1 and Table S1),
demonstrating the diverse array of genes mutated during the in vivo
evolution of daptomycin resistance. However, apart from the
genes involved in phospholipid biosynthesis, none of the other
genetic mutations were consistently observed across all the pairs. It
is of interest though that several of the mutated genes regulate cell
wall biosynthesis, and have also been implicated in reduced
susceptibility to vancomycin [3]. Furthermore, many are associ-
ated with virulence regulation, and suggest that these daptomycin-
Figure 2. Phospholipid biosynthesis genes are integral to the
development of reduced susceptibility to daptomycin in S.
aureus. (A) The predicted amino acid changes associated with the 11
SNPs identified within mprF.( B) The five mutations identified in cls2
were mapped to four positions in the protein, all within the two N-
terminal transmembrane domains. (C) Six mutations were identified in
pgsA and were mapped to four positions in the protein, three of which
were in transmembrane domains. The ‘A’ numbers correspond to the
daptomycin-nonsusceptible isolates, and the arrows point to the
position of the amino acid change.
doi:10.1371/journal.pone.0028316.g002
Figure 3. Schematic of our working hypothesis for the
functional effect of the observed mutations. mprF mutations
lead to an increase in lysinylation of phosphotidylglycerol (PG) to form
L-PG, and an increase in translocation of this positively charged L-PG to
the outer leaflet of the membrane, leading to electrorepulsion of
daptomycin. In isolation, or in concert with mprF mutations, mutations
in cls2 may lead to altered membrane charge or effect binding of
daptomycin to the membrane. Finally, PgsA is important in the initial
step of phospholipid biosynthesis, converting CDP-diacylglycerol (CDP-
DG) into PG.
doi:10.1371/journal.pone.0028316.g003
S. aureus Genomics and Daptomycin
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hypothesis that needs further evaluation.
Daptomycin induces cell wall thickening and changes in
membrane lipid composition
Given the frequency of mutations associated with phospholipid
biosynthesis, and the presence of mutations in genes that regulate
cell wall turnover (walK, agr, stp1), we characterized the ratio of cell
membrane lipids (PG:L-PG ratio) and cell wall thickness in two
representative clinical pairs (A8819/A8817 and A8796/A8799).
Both these pairs have point mutations in mprF in different locations
of the lysinylation domain (Fig. 2A). Consistent with the described
physiology, the daptomycin-nonsusceptible daughter strain,
A8817, had an increase in L-PG in the cell membrane, with a
drop in the PG:L-PG ratio from 3.7 to 1.2 for A8819/A8817
(P,0.05). For the second pair, despite there being an increase in
L-PG in absolute terms (PG:L-PG ratio of 3.2 to 2.5 for A8796/
A8799), the difference was not significant (P=0.2). It has
previously been shown that subtle changes in L-PG in the outer
membrane leaflet can affect daptomycin susceptibility [9]. In the
same two clinical pairs, we also observed greater cell wall thickness
in both daptomycin-nonsusceptible isolates versus their susceptible
parent strains (Fig. 4), with a mean (6SD) thickness of 35.7 nm
(64.1) and 42.8 nm (65.6) in the susceptible strains (A8819 and
A8796, respectively) versus 48.1 nm (65.9) and 53.2 nm (67.1) in
their corresponding resistant daughter strains (A8817 and A8799,
respectively) (P,0.001 for both). Of note, the genetic mutations in
both these pairs (Table S1) did not clearly explain the increase in
cell wall thickness. Other groups have shown that cell wall
thickness in daptomycin-nonsusceptible strains is not a consistent
finding [14,32], and a more recent analysis suggested that in some
strains it may be due to an increase in wall teichoic acid [33].
Conclusions
We have performed whole genome sequencing of the largest
collection of daptomycin exposed S. aureus strains to date. Our data
show that mutations in genes responsible for phospholipid
biosynthesis appear important for the development of reduced
susceptibility to daptomycin, more specifically, mutations in mprF,
cls2 and pgsA. We hypothesise that mutation in each of these genes
act similarly to reduce the net-negative charge of the cell
membrane leading to electrorepulsion of daptomycin. They may
act in isolation or in concert with each other, particularly for
mutations in mprF and cls2 (Fig. 3). Our data also show that in vivo
pressures in the setting of daptomycin exposure select for a range
of other genetic mutations, including those involving virulence
regulatory genes. Finally, we have shown in select clinical isolates,
the functional significance of the observed genetic mutations by
analysing changes in the cell wall and membrane lipid profiles.
Through use of carefully selected strains and broad-based
genomics, this work provides important insights into the
mechanism of resistance to one of our last-line anti-staphylococcal
antibiotics, daptomycin.
Figure 4. Transmission electron microscopy of two clinical pairs showing a thickening of the cell wall in the daptomycin-
nonsusceptible isolates. (A) and (B) represent A8819 (daptomycin-susceptible) and A8817 (daptomycin-nonsusceptible), respectively. (C) and (D)
represent A8796 (daptomycin-susceptible) and A8799 (daptomycin-nonsusceptible), respectively. P,0.001 for both.
doi:10.1371/journal.pone.0028316.g004
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Figure S1 Phylogenetic analysis of 1230 common single
copy genes found in 12 daptomycin-susceptible Staphy-
lococcus aureus parent strains, with Staphylococcus
epidermidis ATCC 12228 and RP62A used as outgroups
for the analysis.
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Table S1 Mutations identified between daptomycin-
susceptible and isogenic daptomycin-nonsusceptible
strains of Staphylococcus aureus.
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Text S1 More detailed methods.
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